A5043219897- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- Monoclonal and Polyclonal Antibodies Research
- Lung Cancer Treatments and Mutations
- Peptidase Inhibition and Analysis
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Estrogen and related hormone effects
- BRCA gene mutations in cancer
- Colorectal Cancer Treatments and Studies
- Brain Metastases and Treatment
- Angiogenesis and VEGF in Cancer
- PI3K/AKT/mTOR signaling in cancer
- PARP inhibition in cancer therapy
- Cancer Risks and Factors
- Chemotherapy-induced cardiotoxicity and mitigation
- Menopause: Health Impacts and Treatments
- Cancer Immunotherapy and Biomarkers
- Breast Lesions and Carcinomas
- Cancer survivorship and care
- Breast Implant and Reconstruction
- Radiopharmaceutical Chemistry and Applications
- Cancer Cells and Metastasis
Rush University Medical Center
2016-2025
University of Illinois Chicago
1981-2024
Sidney Kimmel Cancer Center
2002-2023
Research Network (United States)
1999-2023
Kaiser Permanente
1999-2023
University of Southern California
2002-2023
Washington University in St. Louis
2023
Rush University
1994-2022
University of Ulsan
2021
Asan Medical Center
2021
In an open-label, randomized, phase 3 trial, we compared the efficacy and safety of paclitaxel with that plus bevacizumab, a monoclonal antibody against vascular endothelial growth factor, as initial treatment for metastatic breast cancer.
PURPOSE: To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with HER2-overexpressing metastatic breast cancer. PATIENTS AND METHODS: One hundred fourteen cancer were randomized to receive first-line treatment 4 mg/kg loading dose, followed by 2 weekly, or a higher 8 weekly. RESULTS: The objective response rate was 26% (95% confidence interval [CI], 18.2% 34.4%), seven complete 23 partial responses. Response rates 111 assessable patients 3+ 2+ HER2...
PURPOSE: Overexpression of the HER2 protein occurs in 25% to 30% human breast cancers and leads a particularly aggressive form disease. Efficacy safety recombinant humanized anti-HER2 monoclonal antibody as single agent was evaluated women with HER2-overexpressing metastatic cancer that had progressed after chemotherapy for PATIENTS AND METHODS: Two hundred twenty-two women, one or two regimens, were enrolled. Patients received loading dose 4 mg/kg intravenously, followed by 2-mg/kg...
PURPOSE: To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with HER2-overexpressing metastatic breast cancer. PATIENTS AND METHODS: One hundred fourteen cancer were randomized to receive first-line treatment 4 mg/kg loading dose, followed by 2 weekly, or a higher 8 weekly. RESULTS: The objective response rate was 26% (95% confidence interval [CI], 18.2% 34.4%), seven complete 23 partial responses. Response rates 111 assessable patients 3+ 2+ HER2...
PURPOSE This is the first published report on validation of Functional Assessment Cancer Therapy-Breast (FACT-B), a 44-item self-report instrument designed to measure multidimensional quality life (QL) in patients with breast cancer. The FACT-B consists FACT-General (FACT-G) plus Breast Subscale (BCS), which complements general scale items specific QL was developed an emphasis patients' values and brevity available nine languages. METHODS AND RESULTS Two samples were used for this report. (n...
This randomized phase III trial compared the efficacy and safety of capecitabine with or without bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in patients metastatic breast cancer previously treated an anthracycline taxane.Patients were randomly assigned receive (2,500 mg/m2/d) twice daily on day 1 through 14 every 3 weeks, alone combination bevacizumab (15 mg/kg) 1. The primary end point was progression-free survival (PFS), as determined by independent review...
To define the incidence of BRCA1 mutations among patients seen in clinics that evaluate risk breast cancer, we analyzed DNA samples from women this setting and constructed probability tables to provide estimates likelihood finding a mutation individual families.
No biomarkers have been identified to predict outcome with the use of an antiangiogenesis agent for cancer. Vascular endothelial growth factor (VEGF) genetic variability has associated altered risk breast cancer and variable promoter activity. Therefore, we evaluated association VEGF genotype efficacy toxicity in E2100, a phase III study comparing paclitaxel versus plus bevacizumab as initial chemotherapy metastatic
Sunitinib is an oral, multitargeted tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR), platelet-derived receptor, stem cell (KIT), and colony-stimulating factor-1 receptor. This phase II, open-label, multicenter study evaluated sunitinib monotherapy in patients with metastatic breast cancer (MBC).Sixty-four previously treated anthracycline a taxane received 50 mg/d 6-week cycles (4 weeks on, then 2 off treatment). The primary end point was objective...
Purpose This randomized, multicenter, phase III trial evaluated the efficacy and safety of trastuzumab paclitaxel with or without carboplatin as first-line therapy for women HER-2–overexpressing metastatic breast cancer (MBC). Patients Methods HER-2 overexpression was defined immunohistochemical staining scores 2+ 3+. Between November 1998 May 2002, 196 MBC were randomly assigned to six cycles either 4 mg/kg loading dose plus 2 weekly thereafter 175 mg/m every 3 weeks (TP), area under...
Abstract Purpose: Based on promising preclinical data, we conducted a single-arm phase II trial to assess the clinical benefit rate (CBR) of neratinib, defined as complete/partial response (CR/PR) or stable disease (SD) ≥24 weeks, in HER2mut nonamplified metastatic breast cancer (MBC). Secondary endpoints included progression-free survival (PFS), toxicity, and circulating tumor DNA (ctDNA) detection. Experimental Design: Tumor tissue positive for was required eligibility. Neratinib...
Overexpression of the HER2 protein occurs in 25% to 30% human breast cancers and leads a particularly aggressive form disease. Efficacy safety recombinant humanized anti-HER2 monoclonal antibody as single agent was evaluated women with HER2-overexpressing metastatic cancer that had progressed after chemotherapy for
In a pivotal phase III trial, the addition of trastuzumab to chemotherapy significantly improved response rate, time disease progression, and overall survival in women with HER2 overexpressing metastatic breast cancer. We conducted an extension study this trial obtain additional safety information provide following progression.A total 247 patients documented progression received weekly intravenous study. Concurrent therapies were administered at discretion treating physician. Patient groups...
Ten years after BRCA1 and BRCA2 were first identified as major breast cancer susceptibility genes, the spectrum of mutations modifiers risk among many ethnic minorities remain undefined.To characterize clinical predictors, spectrum, frequency in an ethnically diverse high-risk clinic population to evaluate performance BRCAPRO statistical model predicting likelihood a mutation.Comparative analysis families (white, Ashkenazi Jewish, African American, Hispanic, Asian) with 2 or more cases...
Abstract Purpose: This study, along with two others, was done to develop the 21-gene Recurrence Score assay (Oncotype DX) that validated in a subsequent independent study and is used aid decision making about chemotherapy estrogen receptor (ER)–positive, node-negative breast cancer patients. Experimental Design: Patients ≥10 nodes diagnosed from 1979 1999 were identified. RNA extracted paraffin blocks, expression of 203 candidate genes quantified using reverse transcription-PCR (RT-PCR)....
HER2 mutations (HER2mut) induce endocrine resistance in estrogen receptor-positive (ER+) breast cancer.In this single-arm multi-cohort phase II trial, we evaluated the efficacy of neratinib plus fulvestrant patients with ER+/HER2mut, non-amplified metastatic cancer (MBC) fulvestrant-treated (n = 24) or fulvestrant-naïve cohort 11). Patients ER-negative (ER-)/HER2mut MBC received monotherapy an exploratory ER- 5).The clinical benefit rate [CBR (95% confidence interval)] was 38% (18%-62%), 30%...
To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with
Triple-negative breast cancer (TNBC) is an aggressive subtype of with a poor prognosis particularly in the metastatic setting. Treatments anti-programmed cell death protein-1/programmed death-ligand 1 (PD-L1) immune checkpoint inhibitors (ICI) combination chemotherapies have demonstrated promising clinical benefit TNBC (mTNBC) but there still unmet need, for patients PD-L1 negative tumors. Mechanisms resistance to ICIs mTNBC include presence immunosuppressive tumor-associated macrophages...